Lacosamide Tablet
Product Images NDC 14445-132

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 14445-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indoco Remedies Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100-mg (100 mg)

Lacosamide Tablets USP 100 mg oral tablets. The label includes dosing and storage instructions, a barcode, and indicates the package contains 60 tablets. Manufactured by Indoco Remedies Limited, India, the label features the NDC 14445-130-60 and notes that this product is prescription only.*

FDA Label Image

150-mg (150 mg)

Lacosamide Tablets, USP 150 mg oral tablets label from Indoco Remedies Limited. The label states 60 tablets per container, includes the NDC 14445-131-60, and storage instructions at 20° to 25°C with allowable excursions. It includes a barcode and cautions pharmacists to provide the Medication Guide to patients.*

FDA Label Image

200-mg (200 mg)

Label for Lacosamide Tablets, USP 200 mg, oral tablet by Indoco Remedies Limited. The label includes the strength (200 mg), quantity (60 tablets), prescription status (Rx only), manufacturer details in India, barcode, storage instructions, and a note that each tablet contains 200 mg of Lacosamide, USP.*

FDA Label Image

50-mg (50 mg)

Label for Lacosamide Tablets, USP 50 mg oral tablets by Indoco Remedies Limited. The label indicates a package size of 60 tablets, includes the NDC number 14445-129-60, storage instructions, usual dosage reference, and a notice for pharmacists regarding the accompanying Medication Guide. The label also features manufacturing details and a barcode.*

FDA Label Image

Fig1 (Figure1)

Bar chart showing median percent seizure reduction from baseline in three separate studies comparing placebo to Lacosamide tablets at various dosages (200, 400, 600 mg/day). The vertical axis represents percent seizure reduction, while the horizontal axis shows different studies and treatment groups. Lacosamide tablets demonstrate higher seizure reduction percentages than placebo in all studies, with some differences marked as statistically significant.*

FDA Label Image

Fig2 (Figure2)

A cumulative responder rate chart comparing placebo and Lacosamide tablets at 200 mg/day, 400 mg/day, and 600 mg/day doses. The X-axis shows percent of patients from 0 to 100, while the Y-axis indicates responder rate from -100% to 100%, with improvement above zero and worsening below zero. Four curves show responder rates across treatment groups with sample sizes noted in the legend.*

FDA Label Image

Str (Structure)

Chemical structure of lacosamide, showing the molecular arrangement including an amide group, a methoxy group, and a benzyl group characteristic of the lacosamide molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.